Robert Hazlett
Stock Analyst at BTIG
(1.29)
# 3,684
Out of 5,149 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.24 | +284.62% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $68.11 | -11.91% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.38 | +914.49% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $1.24 | +80,545.16% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $164.05 | -40.26% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.68 | +956.34% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $6.95 | +806.47% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.36 | +209.83% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $0.95 | +2,736,742.11% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.22 | +391.80% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $15.61 | +15.31% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.24
Upside: +284.62%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $68.11
Upside: -11.91%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.38
Upside: +914.49%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $1.24
Upside: +80,545.16%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $164.05
Upside: -40.26%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.68
Upside: +956.34%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.95
Upside: +806.47%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.36
Upside: +209.83%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $0.95
Upside: +2,736,742.11%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.22
Upside: +391.80%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $15.61
Upside: +15.31%